Vanguard Group Inc. Boosts Stake in OrthoPediatrics Corp. $KIDS

Key Points

• Vanguard Group Inc. increased its stake in OrthoPediatrics Corp. by 1.5%, now holding approximately 3.86% of the company, worth $23.10 million.
• Research analysts have mixed ratings on OrthoPediatrics, with a consensus target price of $34.14 and several analysts rating it a "Buy".
• The company reported a quarterly loss with an earnings per share of ($0.11), beating expectations of ($0.17), although it had a negative net margin of 18.92%.

Vanguard Group Inc. raised its position in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 1.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 937,969 shares of the company's stock after purchasing an additional 14,079 shares during the quarter. Vanguard Group Inc. owned 3.86% of OrthoPediatrics worth $23,102,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in OrthoPediatrics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock valued at $228,000 after buying an additional 2,338 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of OrthoPediatrics by 4,618.2% in the 1st quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock valued at $261,000 after acquiring an additional 10,391 shares in the last quarter. Deutsche Bank AG increased its position in shares of OrthoPediatrics by 57.1% in the fourth quarter. Deutsche Bank AG now owns 14,393 shares of the company's stock valued at $334,000 after acquiring an additional 5,233 shares during the last quarter. Numerai GP LLC acquired a new stake in shares of OrthoPediatrics in the fourth quarter valued at about $372,000. Finally, Invesco Ltd. raised its holdings in OrthoPediatrics by 3.0% during the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company's stock worth $379,000 after acquiring an additional 469 shares in the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of OrthoPediatrics stock in a transaction that occurred on Thursday, August 21st. The stock was acquired at an average price of $19.41 per share, with a total value of $98,525.16. Following the transaction, the chief financial officer owned 213,065 shares in the company, valued at $4,135,591.65. This trade represents a 2.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 31.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on KIDS shares. JMP Securities set a $35.00 target price on shares of OrthoPediatrics and gave the stock a "market outperform" rating in a report on Friday, August 8th. Citigroup restated a "market outperform" rating on shares of OrthoPediatrics in a research note on Friday, August 8th. BTIG Research lowered their price target on OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research report on Thursday, May 8th. Finally, Piper Sandler dropped their price target on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.14.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS traded down $0.26 during midday trading on Tuesday, reaching $21.10. The company's stock had a trading volume of 38,151 shares, compared to its average volume of 195,757. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.43 and a current ratio of 6.66. The company has a market cap of $528.98 million, a P/E ratio of -11.79 and a beta of 1.06. The business's 50 day moving average price is $21.15 and its two-hundred day moving average price is $22.07. OrthoPediatrics Corp. has a fifty-two week low of $16.59 and a fifty-two week high of $33.14.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. The business had revenue of $61.08 million during the quarter, compared to analysts' expectations of $61.40 million. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. OrthoPediatrics has set its FY 2025 guidance at EPS. On average, analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.